Northsea Therapeutics’ oral therapy candidate icosabutate was not superior to a placebo at resolving metabolic dysfunction-associated steatohepatitis (MASH) — a severe form of…
Treatment with Akero Therapeutics’ investigational efruxifermin led to reversals of compensated cirrhosis, or irreversible scarring in a still-functioning liver, among adults with metabolic dysfunction-associated…
Long-term treatment with Rezdiffra (resmetirom) reduces liver scarring for most people with compensated cirrhosis, or irreversible scarring in a still-functioning liver, due to metabolic…
Groundhog Day is probably my favorite holiday. It’s pretty noncontroversial, really. Unless you really hate winter, you probably don’t have any problems with Punxsutawney Phil…
Researchers have developed an algorithm to identify people with metabolic dysfunction-associated steatotic liver disease (MASLD), a type of fatty liver disease, based on information…
D&D Pharmatech has finished enrolling a Phase 2 clinical trial of its experimental therapy DD01 in overweight or obese adults with metabolic dysfunction-associated steatohepatitis…
Long-term exposure to air pollution from traffic, even at relatively low concentrations, may increase the risk of fatty liver disease, according to a new…
A virtual clinic for liver diseases, including hepatitis, has begun treating patients. The LiverRight Hepatology Clinic offers same-week video visits to adults who…
Weight loss surgery significantly lowers the risk of serious liver complications among obese people with cirrhosis, or irreversible liver scarring and damage, due to metabolic…
Daily treatment with the investigational oral therapy lanifibranor — used alone or in combination with the diabetes medication Jardiance (empagliflozin) — led to improvements…
